000302119 001__ 302119
000302119 005__ 20250622021254.0
000302119 0247_ $$2doi$$a10.1148/radiol.241030
000302119 0247_ $$2pmid$$apmid:40525978
000302119 0247_ $$2ISSN$$a0033-8419
000302119 0247_ $$2ISSN$$a1527-1315
000302119 0247_ $$2altmetric$$aaltmetric:178148899
000302119 037__ $$aDKFZ-2025-01251
000302119 041__ $$aEnglish
000302119 082__ $$a610
000302119 1001_ $$00000-0001-8786-8686$$aMayerhoefer, Marius E$$b0
000302119 245__ $$aUpdate on Liquid Biopsy.
000302119 260__ $$aOak Brook, Ill.$$bSoc.$$c2025
000302119 3367_ $$2DRIVER$$aarticle
000302119 3367_ $$2DataCite$$aOutput Types/Journal article
000302119 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1750252884_1996$$xReview Article
000302119 3367_ $$2BibTeX$$aARTICLE
000302119 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000302119 3367_ $$00$$2EndNote$$aJournal Article
000302119 520__ $$aLiquid biopsy helps detect cells and cell-derived metabolites, proteins, nucleic acids, and vesicles that are shed into body fluids by tumors. This diagnostic test requires only approximately 10 mL of blood or urine. It has received considerable attention as a minimally invasive tool for whole-body tumor interrogation for use in patients with cancer. It poses an attractive and potentially cost-effective alternative to invasive tissue sampling through tissue biopsies, especially serial assessments, such as for treatment response evaluation and mutations that occur during cancer treatment. Cell-free and circulating tumor DNA are the most frequently tested liquid biopsy analytes, and have shown promise for cancer screening, assessment of residual disease after treatment, and clinical outcome prediction and prognostication. Whereas liquid biopsy is less sensitive than imaging in early tumor stages, it is more specific and may help detect treatment response earlier than the Response Evaluation Criteria in Solid Tumors, or RECIST. Aimed primarily at radiologists, this review article provides an update on recent developments in the use of liquid biopsy, including findings from landmark clinical trials and U.S. regulatory approvals as companion diagnostic tests for clinical use, particularly in four malignancies: lymphoma, breast cancer, prostate cancer, and melanoma. Finally, current challenges for the clinical implementation of liquid biopsy are discussed.
000302119 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000302119 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000302119 650_7 $$2NLM Chemicals$$aBiomarkers, Tumor
000302119 650_7 $$2NLM Chemicals$$aCirculating Tumor DNA
000302119 650_2 $$2MeSH$$aHumans
000302119 650_2 $$2MeSH$$aLiquid Biopsy: methods
000302119 650_2 $$2MeSH$$aNeoplasms: pathology
000302119 650_2 $$2MeSH$$aNeoplasms: diagnosis
000302119 650_2 $$2MeSH$$aBiomarkers, Tumor: blood
000302119 650_2 $$2MeSH$$aCirculating Tumor DNA: blood
000302119 7001_ $$0P:(DE-He78)e584a92f41b005cab185e57fcc2a0957$$aKienzle, Andreas$$b1$$udkfz
000302119 7001_ $$00000-0001-8459-8369$$aWoo, Sungmin$$b2
000302119 7001_ $$00000-0003-1169-133X$$aVargas, Hebert Alberto$$b3
000302119 773__ $$0PERI:(DE-600)2010588-5$$a10.1148/radiol.241030$$gVol. 315, no. 3, p. e241030$$n3$$pe241030$$tRadiology$$v315$$x0033-8419$$y2025
000302119 909CO $$ooai:inrepo02.dkfz.de:302119$$pVDB
000302119 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e584a92f41b005cab185e57fcc2a0957$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000302119 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000302119 9141_ $$y2025
000302119 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bRADIOLOGY : 2022$$d2024-12-12
000302119 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-12
000302119 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-12
000302119 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-12
000302119 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-12
000302119 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-12
000302119 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-12
000302119 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-12
000302119 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-12
000302119 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-12
000302119 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-12
000302119 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bRADIOLOGY : 2022$$d2024-12-12
000302119 9201_ $$0I:(DE-He78)D410-20160331$$kD410$$lImmuntherapie und -prävention$$x0
000302119 980__ $$ajournal
000302119 980__ $$aVDB
000302119 980__ $$aI:(DE-He78)D410-20160331
000302119 980__ $$aUNRESTRICTED